Medical Information Only. Consult your healthcare provider before considering clinical trial enrollment.
IgG4 Related Disease: full-pipeline trial registry
2 of 5 indexed IgG4 Related Disease trials are currently recruiting.
Corpus placement: #3,391 of 28,707 conditions by registered trial count.
5 US clinical trials · 2 currently recruiting · #3,391 of 28,707 conditions by registered trial count
IgG4 Related Disease: 5 US clinical trials tracked, 2 recruiting.
IgG4 Related Disease is the subject of 5 registered US clinical trials on ClinicalTrials.gov, 2 of them currently open to new participants. 2 are in Phase 3-4 (later-stage) and 3 in Phase 1-2 (earlier-stage). The most active sponsor is Acepodia Biotech, running 1 of these trials.
Enrollment posture brief
Registry condition igg4-related-disease
OPEN 2 | RECR 40% | LATE 2 | EARLY 3 | RANK #3391 | SPON 1
Volume-matched condition peers
Nearest open-share peer: Achondroplasia (40% recruiting · 10 trials)
IgG4 Related Disease lists 2 open slots (40% of 5 indexed trials). Peers are matched on registered volume, not therapeutic-area browse lists. How peer matching works →
Key findings
What ClinicalTrials.gov does not surface for IgG4 Related Disease on its own pages , computed from the registry mirror as of 2026-08-08. Each line carries its own denominator so it can be quoted as it stands.
-
IgG4 Related Disease is recruiting below its size-band peers.
2 of 5 indexed trials (40%) are open to enrollment, against a 46.5% average across 27,806 conditions with fewer than 20 trials. The peer set uses the same ClinicalTrials.gov-derived counts as this page.
-
One sponsor concentrates IgG4 Related Disease research.
Acepodia Biotech accounts for 1 of 5 trials (20%). 5 distinct sponsors appear on at least one study for this condition label.
-
Most IgG4 Related Disease trials plan to enrol fewer than 100 people.
Median target enrolment is 30 among the 5 trials that report a genuine target (sentinel values excluded). 3 of those (60%) plan for fewer than 100 participants.
-
IgG4 Related Disease research is mostly interventional.
5 interventional and 0 observational studies make up this index (100% interventional). Study type is sponsor-reported on ClinicalTrials.gov.
Open and recent trials
5 total, page 1 of 1
Study to Assess Safety, Efficacy and Persistence of ACE1831, in Subjects With IgG4-Related Disease
Acepodia Biotech
NCT07061938
A Study of Efgartigimod in Patients With IgG4-Related Disease
Stanford University
NCT07025330
A Phase 3 Study of Obexelimab in Patients With IgG4-Related Disease
Zenas BioPharma (USA)
NCT05662241
A Study of Inebilizumab Efficacy and Safety in IgG4- Related Disease
Amgen
NCT04540497
Treatment of IgG4-Related Disease With Revlimid and Rituximab
Mayo Clinic
NCT02705638
Phase Distribution
| Phase | Trial count |
|---|---|
| Phase 1 | 2 |
| Phase 2 | 1 |
| Phase 3 | 2 |
Top Sponsors
Named interventions
Most-linked intervention names on IgG4 Related Disease records (sponsor-reported on ClinicalTrials.gov). Counts are trial links, not unique products.
US sites by state
Facility locations filed on IgG4 Related Disease trials. A trial with sites in several states counts in each.
Source: ClinicalTrials.gov, National Library of Medicine. Data is informational only.
Related
What to do with this IgG4 Related Disease page
5 registered trials, 2 currently recruiting, is a starting point for a conversation, not a diagnosis or a recommendation.
- 2 IgG4 Related Disease trials are currently recruiting, check eligibility criteria before contacting a site. Browse recruiting trials
- Acepodia Biotech sponsors the most IgG4 Related Disease trials on record, review their full trial history before evaluating a specific study. See Acepodia Biotech's trials
- Bring the specific trial ID (NCT number) to your own doctor before enrolling, this page is a directory, not medical guidance. Read the trial-finding guide
Trial and recruiting counts reflect ClinicalTrials.gov registry status as of the data vintage above; individual trial eligibility and enrollment status can change.
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This IgG4 Related Disease condition card totals 5 registered trials; most-linked intervention Placebo; top US site state Massachusetts. See our editorial standards & corrections policy, the methodology behind these numbers, the data changelog, or report a data error.